Forazapadin not checked
Satellos Bioscience, Inc. · SAT-3247
FollowEvery change as it happens, and a Monday email
Trials
3 active
3 in total · 1 in the EU
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “SAT-3247 is a selective AAK1 inhibitor for oral tablet administration which promotes functional rescue of asymmetric satellite cell division, resulting in the robust production of muscle progenitor cells, subsequent improvement in muscle regeneration, and enhanced muscle function.”In the company’s words, NCT07287189 on ClinicalTrials.gov
- Tested for
- Duchenne Muscular Dystrophy, Duchenne, DMD, Neuromuscular Diseases, Muscular Dystrophies, Duchenne Muscular Dystrophy (DMD), Facioscapulohumeral Muscular Dystrophy (FSHD)
- Main trialPhase 2
- “Phase 2a trial of SAT-3247 in ambulatory DMD patients aged ≥ 7 and \< 10 years. The trial has two parts. In Part 1, the trial will study two doses of SAT-3247 in a randomized, double-blind, placebo-controlled weekday regimen for 12 weeks to determine the optimal dose, safety, tolerability, and preliminary efficacy. In Part 2, the trial will study two doses of SAT-3247 for an additional 9 months.”In the company’s words, NCT07287189 on ClinicalTrials.gov
- Other names
- SAT-3247
Other drugs for Duchenne Muscular Dystrophy
- AOC 1044Avidity Biosciences, Inc. · Phase 3
- GivinostatItalfarmaco · Phase 3
- SGT-003Solid Biosciences Inc. · Phase 3
- Zeleciment RostudirsenDyne Therapeutics · Phase 3
- DeramiocelCapricor Inc. · Phase 3
- DS-5141bDaiichi Sankyo · Phase 2
Coming up3
- 31 Mar 2027Phase 2 trial completes · ClinicalTrials.gov
- 30 Sep 2027Phase 2 trial completes · ClinicalTrials.gov
- 30 Dec 2028Phase 2 trial completes · ClinicalTrials.gov
Changes1
Last 90 days- 19 NovStatus changed: Enrolling by invitation to Recruiting · ClinicalTrials.gov NCT06867107
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Active, not recruiting | 31 Mar 2027 | Phase 2 Study of SAT-3247 in Pediatric Ambulatory Patients | |
| Phase 2Recruiting | 30 Sep 2027 | An Open-label Long-term Follow-up Study of SAT-3247 for Participants With Duchenne Muscular Dystrophy Including Those Who Participated in SAT-3247-CL-101 | |
| Phase 2Not yet recruiting | 30 Dec 2028 | A Study of SAT-3247 to Evaluate the Safety, Tolerability, and Efficacy in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026